Inquiry Basket
Loading ......
Aspergillus fumigatus is a saprophytic filamentous fungus found ubiquitously in the environment, particularly in soil, decaying organic matter, compost piles, and indoor air. It produces vast numbers of small, hydrophobic conidia (spores) that are easily aerosolized and inhaled by humans on a daily basis. In healthy individuals, these spores are efficiently cleared by the innate immune system without causing disease. However, in immunocompromised individuals—such as those undergoing chemotherapy, solid organ or stem cell transplantation, prolonged corticosteroid therapy, or those with advanced HIV/AIDS—A. fumigatus can cause a spectrum of diseases ranging from allergic reactions to life-threatening invasive aspergillosis. Among the various diagnostic approaches for aspergillosis, serological detection of specific antibodies, particularly IgG, plays a critical role in the diagnosis of chronic and allergic forms of the disease.
Figure 1.Aspergillus fumigatus.
Aspergillus fumigatus is a thermotolerant fungus that grows optimally at 37°C and can survive at temperatures up to 55°C. This thermotolerance is a key virulence factor, allowing the fungus to thrive in the human host. The life cycle of A. fumigatus begins with the production of asexual conidia from specialized structures called phialides on the conidiophore. These conidia are 2–3 micrometers in diameter, a size that allows them to reach the alveoli of the lungs when inhaled. Under favorable conditions, conidia germinate to form hyphae, which are septate and branching. The hyphae can invade lung tissue and blood vessels, leading to angioinvasion, thrombosis, and tissue necrosis. The fungus reproduces asexually, releasing large numbers of conidia that can be dispersed by air currents, perpetuating the environmental reservoir.
Several virulence factors contribute to the pathogenicity of A. fumigatus. The rodlet layer on the conidial surface, composed of a protein called RodA, masks immunostimulatory molecules and allows the conidia to evade recognition by the host immune system. Melanin, a dark pigment present in the conidial cell wall, protects against oxidative stress and phagocytic killing. The fungus produces a variety of secreted proteases (including proteases, phospholipases, and phosphatases) that degrade host tissue, facilitating invasion and nutrient acquisition. Gliotoxin, a mycotoxin produced by A. fumigatus, suppresses the host immune response by inducing apoptosis in immune cells and inhibiting phagocytosis. Additionally, the ability of the fungus to form biofilms on medical devices and within lung cavities contributes to treatment resistance and chronic infection.
Infection with A. fumigatus can result in several distinct clinical entities depending on the host immune status.
| Key Molecular Targets | Details |
| Allergic Forms | In atopic individuals, inhalation of A. fumigatus conidia can trigger allergic bronchopulmonary aspergillosis (ABPA), a hypersensitivity reaction characterized by wheezing, pulmonary infiltrates, bronchiectasis, and elevated total and Aspergillus-specific IgE. Chronic eosinophilic pneumonia and allergic rhinitis can also occur. |
| Chronic Forms | Chronic pulmonary aspergillosis (CPA) occurs in patients with underlying lung disease (such as tuberculosis, chronic obstructive pulmonary disease, or sarcoidosis) but without severe immunocompromise. CPA presents with weight loss, cough, hemoptysis, and fatigue. Aspergilloma, a fungal ball within a pre-existing lung cavity, is a common manifestation. In these chronic conditions, patients typically mount a strong antibody response, making IgG detection a valuable diagnostic tool. |
| Invasive Aspergillosis | Invasive aspergillosis (IA) occurs almost exclusively in severely immunocompromised patients. The fungus invades lung parenchyma and blood vessels, causing hemorrhagic infarction, necrosis, and dissemination to other organs. IA carries a high mortality rate, exceeding 50% even with treatment. Diagnosis of IA is challenging and often relies on detection of galactomannan antigen or PCR, because antibody responses are frequently absent due to the lack of functional immune system. |
Upon inhalation of A. fumigatus conidia, the innate immune system is the first line of defense. Alveolar macrophages phagocytose and kill conidia, while neutrophils and other phagocytes attack hyphae. In healthy individuals, this response clears the organism without symptoms. In chronic infections, however, a robust adaptive immune response develops. B cells produce antibodies against various fungal antigens, including secreted proteases, cell wall components, and other immunogenic proteins. Among these antibodies, IgG is the most abundant and persistent immunoglobulin in chronic fungal diseases. Elevated Aspergillus-specific IgG is considered a hallmark of chronic and allergic aspergillosis, particularly CPA and aspergilloma. In contrast, patients with invasive aspergillosis often fail to produce detectable levels of specific IgG due to profound immunosuppression. Therefore, measurement of Aspergillus-specific IgG is most clinically useful in non-neutropenic patients with suspected chronic pulmonary aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis.
The Human Aspergillus Fumigatus IgG ELISA Kit is a commercially available, ready-to-use assay designed for the specific and sensitive detection of IgG antibodies against A. fumigatus in human serum or plasma. The kit is intended for in vitro diagnostic use as an aid in the diagnosis of chronic pulmonary aspergillosis, aspergilloma, allergic bronchopulmonary aspergillosis, and other diseases where Aspergillus-specific IgG is part of the diagnostic criteria. It offers several advantages: high sensitivity and specificity, standardized format, ease of use (fits into routine clinical laboratory workflows), relatively short assay time, and quantifiable results. When using such a kit, a positive result should be interpreted in the context of the patient's clinical presentation, imaging findings, and other laboratory tests. A negative result does not completely exclude aspergillosis, particularly in immunocompromised patients who may not mount an antibody response.
Anti-Aspergillus monoclonal antibody refers to a highly specific antibody produced from a single B-cell clone that recognizes a single epitope on an Aspergillus fumigatus antigen. Monoclonal antibodies are invaluable tools in diagnostic development and research. They can be used in several contexts related to the IgG ELISA kit. First, they serve as critical reagents for the development and quality control of the ELISA kit itself. For example, a monoclonal antibody directed against a conserved A. fumigatus antigen can be used as a capture antibody in a sandwich ELISA format, or as a detection antibody when conjugated to an enzyme. Second, they can be used as positive controls or calibrators to standardize the assay across different lots and laboratories. Third, they allow the detection of specific antigenic components in patient samples, complementing the measurement of anti-Aspergillus antibodies. Beyond diagnostic kits, anti-Aspergillus monoclonal antibodies are being explored as therapeutic agents for invasive aspergillosis, either alone or conjugated to antifungal drugs or toxins. Such therapeutic monoclonal antibodies may enhance opsonization, neutralization of virulence factors, or direct killing of fungal cells.
Aspergillus fumigatus is a ubiquitous fungal pathogen capable of causing a wide spectrum of diseases, from allergic syndromes to life-threatening invasive infection. The host immune response, particularly the production of Aspergillus-specific IgG, is a hallmark of chronic and allergic forms of aspergillosis. The Human Aspergillus Fumigatus IgG ELISA Kit provides a sensitive, specific, and convenient method for detecting these antibodies in patient serum, playing an essential role in the diagnosis of chronic pulmonary aspergillosis, aspergilloma, and allergic bronchopulmonary aspergillosis. The kit relies on well-characterized A. fumigatus antigens and can be used in conjunction with Anti-Aspergillus monoclonal antibodies as critical reagents for development, quality control, and standardization. While the test has limitations—particularly in the diagnosis of invasive disease—it remains an indispensable tool in the clinical mycology laboratory. By understanding both the pathogen biology of A. fumigatus and the strengths and weaknesses of IgG ELISA detection, clinicians and laboratorians can optimize the diagnosis and management of patients suffering from this important fungal disease.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA313 | Human Aspergillus Fumigatus IgA ELISA Kit | 96T | Human | Quantitative | iELISA | Inquiry |
| DEIA314 | Human Aspergillus Fumigatus IgM ELISA Kit | 96T | Human | Quantitative | iELISA | Inquiry |
| DEIA312 | Human Aspergillus Fumigatus IgG ELISA Kit | 96T | Human | Quantitative | iELISA | Inquiry |
Loading ......
